InDex Pharmaceuticals Holding (OM:INDEX) - Cotización, noticias y análisis

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Resumen de acción INDEX

InDex Pharmaceuticals Holding AB (publ) se dedica a la investigación y desarrollo de fármacos para enfermedades inmunológicas. Saber más

Análisis fundamental de INDEX
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Los beneficios han crecido un 2.7% al año en los últimos 5 años

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 48.5% al año durante los próximos 3 años

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

No tiene una capitalización de mercado significativa (SEK287M)

Competidores de InDex Pharmaceuticals Holding AB (publ)

ODI Pharma

NGM:ODI

SEK 48.7m

Ziccum

OM:ZICC

SEK 15.9m

Corline Biomedical

OM:CLBIO

SEK 138.0m

AcuCort

NGM:ACUC

SEK 99.9m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de InDex Pharmaceuticals Holding
Precios históricos de las acciones
Precio actual de la acción	SEK 0.55
Máximo en las últimas 52 semanas	SEK 0.93
Mínimo de 52 semanas	SEK 0.20
Beta	-0.21
1Cambio en 1 mes	35.15%
Variación en 3 meses	88.28%
Cambio de 1 año	-4.55%
3Variación en 3 años	-63.84%
Variación en 5 años	-93.87%
Variación desde la OPV	-92.20%

Noticias y actualizaciones recientes

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21

Rentabilidad de los accionistas

	INDEX	SE Pharmaceuticals	Mercado SE
7D	1.1%	-5.5%	-2.4%
1Y	-4.5%	9.1%	10.9%

Rentabilidad vs. Industria: Los resultados de INDEX fueron inferiores a los de la industria Swedish Pharmaceuticals, que obtuvo un rendimiento del 9.1% el año pasado.

Rentabilidad vs. Mercado: INDEX obtuvo unos resultados inferiores a los del mercado Swedish, que fueron del 10.9% el año pasado.

Volatilidad de los precios

Is INDEX's price volatile compared to industry and market?
INDEX volatility
INDEX Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	10.6%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Precio estable de las acciones: El precio de las acciones de INDEX ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de INDEX (7%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	4	Jenny Sundqvist	www.indexpharma.com

InDex Pharmaceuticals Holding AB (publ) se dedica a la investigación y el desarrollo de fármacos para enfermedades inmunológicas. La empresa se fundó en 2000 y tiene su sede en Solna (Suecia).

Resumen de fundamentos de InDex Pharmaceuticals Holding AB (publ)

¿Cómo se comparan los beneficios e ingresos de InDex Pharmaceuticals Holding con su capitalización de mercado?
Estadísticas fundamentales de INDEX
Capitalización bursátil	SEK 286.59m
Beneficios(TTM)	-SEK 56.48m
Ingresos (TTM)	SEK 108.34m

2.7x

Ratio precio-ventas (PS)

-5.1x

Ratio precio-beneficio (PE)

¿Está INDEX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de INDEX
Ingresos	SEK 108.34m
Coste de los ingresos	SEK 4.03m
Beneficio bruto	SEK 104.31m
Otros gastos	SEK 160.79m
Beneficios	-SEK 56.48m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

Aug 20, 2024

Beneficios por acción (BPA)	-0.11
Margen bruto	96.28%
Margen de beneficio neto	-52.13%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado INDEX a largo plazo?

Ver rendimiento histórico y comparativa

This company is no longer active

Resumen de acción INDEX

Recompensas

Análisis de riesgos

Competidores de InDex Pharmaceuticals Holding AB (publ)

NGM:ODI

SEK 48.7m

OM:ZICC

SEK 15.9m

OM:CLBIO

SEK 138.0m

NGM:ACUC

SEK 99.9m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Discontinues the Development of Cobitolimod

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

InDex Pharmaceuticals Holding AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.006 loss in 3Q 2022)

New major risk - Share price stability

InDex Pharmaceuticals Holding AB (publ) Discontinues Cobitolimod Phase III Program

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

InDex Pharmaceuticals Holding AB (Publ) Receives New Patent for Cobitolimod in South Korea

InDex Pharmaceuticals Holding AB (publ) Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude

InDex Pharmaceuticals Holding AB (publ) Announces Positive Results from the Pharmacokinetic (PK) Study

InDex Pharmaceuticals Holding AB (publ) Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

Price target decreased by 31% to kr1.90

InDex Pharmaceuticals Holding AB (publ) Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Final Results on Apr 12, 2023

InDex Pharmaceuticals Holding AB (publ) to Report Q1, 2023 Results on May 24, 2023

Third quarter 2022 earnings released: kr0.006 loss per share (vs kr0.05 loss in 3Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) Appoints Jenny Sundqvist as New CEO, Effective January 1, 2023

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Successful Interactions with the Pmda for the Clinical Development of Cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) Announces Board Appointments

First quarter 2022 earnings released: kr0.04 loss per share (vs kr0.02 loss in 1Q 2021)

InDex Pharmaceuticals Strengthens the Organization with Eva Arlander as Chief Development Officer and Announces Changes in the Composition of the Management Team

Full year 2021 earnings released: kr0.21 loss per share (vs kr0.24 loss in FY 2020)

InDex Pharmaceuticals Holding AB (publ) Announces CEO Changes

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Full year 2021 earnings: EPS misses analyst expectations

InDex Pharmaceuticals Holding AB (publ) Announces Resignation of Pernilla Sandwall as Chief Operating Officer

InDex Pharmaceuticals Enrols First Patient in the Pk Study with Cobitolimod

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

InDex Pharmaceuticals Holding AB (publ) Enrolls First Patient in Phase III Study CONCLUDE with Cobitolimod in Ulcerative Colitis

Second quarter 2021 earnings released

InDex Pharmaceuticals Receives FDA Clearance to start the Phase III Study CONCLUDE with Cobitolimod

InDex Pharmaceuticals Holding AB (publ) to Conduct Clinical Pharmacokinetic Study (PK Study) with Cobitolimod in Sweden

InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III study CONCLUDE with Cobitolimod

Independent Director Stig Pedersen has left the company

Independent Director Yilmaz Mahshid has left the company

InDex Pharmaceuticals Holding AB (publ) Announces Patient Recruitment for Phase III Study CONCLUDE is Planned to Initiate after Summer

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding AB (Publ) Announces Changes in the Nomination Committee for the 2021 Annual General Meeting

Revenue in line with expectations

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 23, 2021

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

New 90-day low: kr3.88